AR050966A1 - Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) - Google Patents
Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)Info
- Publication number
- AR050966A1 AR050966A1 ARP050104117A ARP050104117A AR050966A1 AR 050966 A1 AR050966 A1 AR 050966A1 AR P050104117 A ARP050104117 A AR P050104117A AR P050104117 A ARP050104117 A AR P050104117A AR 050966 A1 AR050966 A1 AR 050966A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- substituted
- group
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- AIDS & HIV (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos y condiciones patologicas moduladas por el receptor de androgenos. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 está seleccionado del grupo que consiste en H, alquilo C1-4, -alquil C1-4-O, -alquil C1-4-CN, -alquil C1-4-NO2, -alquil C1-4-N(RARB), -alquil C1-4-CO2H, -(alquil C1-4)-X-R7, -CH2-arilo y -CH2-heteroarilo; en donde el grupo arilo o heteroarilo (en el grupo -CH2-arilo y -CH2-heteroarilo) está opcionalmente sustituido con uno o más sustituyentes seleccionados, de modo independiente, de halogeno, alquilo C1-4, alquiloC1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, - alquil C1-4-CN, -alquil C1-4-OH, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S-alquilo C1-4, -S-(alquilo C1-4 sustituido con halogeno), -SO-alquilo C1-4, -SO2-alquilo C1-4, -O-aralquilo, -C(O)O-alquilo C1-4, -CO2H, -C(O)H, heteroarilo o heterocicloalquilo; en donde RA y RB están seleccionados, de modo independiente, de H o alquilo C1-4; de modo alternativo, RA y RB se toman juntos con el átomo de N al que están unidos para formar una estructura cíclica aromática, parcialmente insaturada o saturada, de 5 a 7 miembros, que contiene opcionalmente 1 o 2 heteroátomos adicionales seleccionados de O, S o N; y en donde la estructura cíclica está opcionalmente sustituida con alquilo C1-4, en donde X está seleccionado del grupo que consiste en -S-, -SO-, -SO2-, -O-SO2-, -O-, -C(OH)-, -C(=N(OH))-, -C(O)-, -C(O)-O-, -NRc-, -NRc-C(O)-, -C(O)-NRc-, -NRc-SO2- y -SO2-NRc-; en donde Rc está seleccionado de H o alquilo C1-4; en donde R7 está seleccionado del grupo que consiste en alquilo C1-4, alquilo C1-4 sustituido con halogeno, alquenilo C2-4, arilo, aralquilo, bifenilo, cicloalquilo, cicloalquil-(alquilo C1-4)-, heteroarilo, heteroaril-(alquilo C1-4)-, heterocicloalquilo y heterocicloaquil-(alquilo C1-4)-; en donde el grupo cicloalquilo, arilo, heteroarilo o heterocicloalquilo, ya sea solo o como parte de un grupo sustituyente, está opcionalmente sustituido con 1 o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S(O)0-2-(alquilo C1-4), -SO2-N(RD)2, arilo, heteroarilo o heterocicloalquilo; en donde cada RD está seleccionado, de modo independiente, de H o alquilo C1-4; con la condicion de que, cuando X es O o NRc, R6 sea distinto de alquenilo C2-4; R2 está seleccionado del grupo que consiste en H, halogeno, alquilo C1-4, alquilo C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -O-alquilo C1-4, -S-alquilo C1-4, -SO-alquilo C1-4, -SO2-alquilo C1-4 y -NRE-C(O)-alquilo C1-4; en donde RE está seleccionado de H o alquilo C1-4; R3 está seleccionado del grupo que consiste en H, halogeno, alquilo C1-4, alquilo C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -O-alquilo C1-4, -S-alquilo C1-4, -SO-alquilo C1-4, -SO2-alquilo C1-4 y -NRF-C(O)- alquilo C1-4; en donde RF está seleccionado de H o alquilo C1-4; con la condicion de que al menos uno de R2 o R3 sea distinto de H; a es un numero entero de 0 a 1; R4 está seleccionado del grupo que consiste en H, alquilo C1-4, alquilo C1-4 sustituido con halogeno y -C(O)-R8; en donde R8 está seleccionado del grupo que consiste en alquilo C1-4, cicloalquilo, cicloalquil-(alquilo C1-4)-, arilo, aralquilo, heteroarilo, heteroaril-(alquilo C1-4)-, heterocicloalquilo y heterocicloalquil- (alquilo C1-4)-, en donde el grupo alquilo, cicloalquilo, arilo, heteroarilo o heterocicloalquilo, ya sea solo o como parte de un grupo sustituyente, está opcionalmente sustituido con uno o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4 o di(alquil C1-4)amino; R5 está seleccionado del grupo que consiste en H, halogeno, alquilo C1-4 y alquilo C1-4 sustituido con halogeno; R6 está seleccionado el grupo que consiste en alquilo C1-4, alquilo C1-4 sustituido con halogeno, -alquil C1-4-OH, -alquil C1-4-CN, -alquil C1-4-NO2, -alquil C1-4-N(RGRH), alquil C1-4- CO2H, -(alquil C1-4)-Y-R9, -CH2-arilo y -CH2-heteroarilo; en donde el arilo o heteroarilo (en el grupo -CH2-arilo o -CH2-heteroarilo) está opcionalmente sustituido con uno o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4- sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S(O)0-2-alquilo C1-4 o -SO2-N(RJ)2; en donde cada RJ está seleccionado, de modo independiente, de H o alquilo C1-4; en done RG y RH están seleccionados, de modo independiente, de H o alquilo C1-4; de modo alternativo, RG y RH se toman juntos con el átomo de N al que están unidos para formar una estructura cíclica aromática, parcialmente insaturada o saturada, de 5 a 7 miembros, que contiene opcionalmente 1 o 2 heteroátomos adicionales seleccionados de O, S o N; y en donde la estructura cíclica está opcionalmente sustituida con alquilo C1-4; en donde Y está seleccionado del grupo que consiste en -S-, -SO-, SO2-, -O-SO2-, -O-, -C(OH)-, -C(=N(OH))-, -C(O)-, -C(O)-O-, -NRk-, -NRk-C(O)-, -C(O)-NRk-, -NRk-SO2- y -SO2-NRk-; en donde Rk está seleccionado de H o alquilo C1-4; en donde R9 está seleccionado del grupo que consiste en alquilo C1-4, alquilo C1-4 sustituido con halogeno, alquenilo C2-4, arilo, aralquilo, bifenilo, cicloalquilo, cicloalquil-(alquilo C1-4)-, heteroarilo, heteroaril-(alquilo C1-4)-, heterocicloalquilo y heterocicloaquil-(alquilo C1-4)-; en donde el grupo cicloalquilo, arilo, heteroarilo o heterocicloalquilo, ya sea solo o como parte de un grupo sustituyente, está opcionalmente sustituido con 1 o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S(O)0-2-(alquilo C1-4), -SO2-N(RL)2 o -NRM-C(O)-alquilo C1-4; en donde cada RL está seleccionado, de modo independiente, de H o alquilo C1-4; y en donde RM está seleccionado de H o alquilo C1-4; con la condicion de que, cuando Y es O o NRk, R9 sea distinto de alquenilo C2-4; con la condicion de que, cuando R4 es H y R5 es H, R6 sea distinto de alquilo C1-4; también con la condicion de que, cuando R1 es H; a es 0; R4 es H y R5 es alquilo C1-4; R6 sea distinto de alquilo C1-4; también con la condicion de que, cuando R1 es H, a es 0; R2 es -O-alquilo C1-4; R3 es H; R4 es H; R5 es H; R6 sea distinto de -CH2-fenilo, en donde el fenilo está sustituido con -O-alquilo C1-4; también con la condicion de que, cuando R1 es H, a es 0, R4 es H y R5 es H, R6 sea distinto de -CH2-(bencimidazolilo), en donde el bencimidazolilo está sustituido con 1 a 2 sustituyentes seleccionados de halogeno, alquilo C1-4 u -O-alquilo C1-4; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61475104P | 2004-09-30 | 2004-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050966A1 true AR050966A1 (es) | 2006-12-06 |
Family
ID=35825468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104117A AR050966A1 (es) | 2004-09-30 | 2005-09-29 | Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) |
Country Status (10)
Country | Link |
---|---|
US (3) | US7566733B2 (es) |
EP (1) | EP1805147B1 (es) |
JP (1) | JP4953456B2 (es) |
CN (1) | CN101065363B (es) |
AR (1) | AR050966A1 (es) |
AU (1) | AU2005292345B9 (es) |
CA (1) | CA2582356A1 (es) |
MY (1) | MY147985A (es) |
TW (1) | TW200621725A (es) |
WO (1) | WO2006039243A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763074B2 (en) | 2004-10-20 | 2010-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for posterior dynamic stabilization of the spine |
US9023084B2 (en) | 2004-10-20 | 2015-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for stabilizing the motion or adjusting the position of the spine |
US8425559B2 (en) | 2004-10-20 | 2013-04-23 | Vertiflex, Inc. | Systems and methods for posterior dynamic stabilization of the spine |
US9161783B2 (en) | 2004-10-20 | 2015-10-20 | Vertiflex, Inc. | Interspinous spacer |
US8277488B2 (en) | 2004-10-20 | 2012-10-02 | Vertiflex, Inc. | Interspinous spacer |
US8409282B2 (en) | 2004-10-20 | 2013-04-02 | Vertiflex, Inc. | Systems and methods for posterior dynamic stabilization of the spine |
US9119680B2 (en) | 2004-10-20 | 2015-09-01 | Vertiflex, Inc. | Interspinous spacer |
US8012207B2 (en) | 2004-10-20 | 2011-09-06 | Vertiflex, Inc. | Systems and methods for posterior dynamic stabilization of the spine |
US8128662B2 (en) | 2004-10-20 | 2012-03-06 | Vertiflex, Inc. | Minimally invasive tooling for delivery of interspinous spacer |
US8317864B2 (en) | 2004-10-20 | 2012-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for posterior dynamic stabilization of the spine |
US8613747B2 (en) | 2004-10-20 | 2013-12-24 | Vertiflex, Inc. | Spacer insertion instrument |
US8167944B2 (en) | 2004-10-20 | 2012-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for posterior dynamic stabilization of the spine |
US8123782B2 (en) | 2004-10-20 | 2012-02-28 | Vertiflex, Inc. | Interspinous spacer |
US8123807B2 (en) | 2004-10-20 | 2012-02-28 | Vertiflex, Inc. | Systems and methods for posterior dynamic stabilization of the spine |
US8152837B2 (en) | 2004-10-20 | 2012-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for posterior dynamic stabilization of the spine |
WO2009009049A2 (en) | 2004-10-20 | 2009-01-15 | Vertiflex, Inc. | Interspinous spacer |
US8945183B2 (en) | 2004-10-20 | 2015-02-03 | Vertiflex, Inc. | Interspinous process spacer instrument system with deployment indicator |
DE602005011844D1 (de) * | 2004-11-02 | 2009-01-29 | Pfizer | Sulfonylbenzimidazolderivate |
AU2008343092B2 (en) | 2004-12-06 | 2014-09-11 | Vertiflex, Inc. | Spacer insertion instrument |
BRPI0706726B8 (pt) | 2006-01-24 | 2021-05-25 | Janssen Pharmaceutica Nv | benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar |
US8845726B2 (en) | 2006-10-18 | 2014-09-30 | Vertiflex, Inc. | Dilator |
EP2155121B1 (en) | 2007-04-16 | 2015-06-17 | Vertiflex, Inc. | Interspinous spacer |
ES2434693T3 (es) * | 2007-04-20 | 2013-12-17 | The Research Foundation For The State University Of New York | Bencimidazoles y composiciones farmacéuticas de los mismos |
WO2009091922A2 (en) | 2008-01-15 | 2009-07-23 | Vertiflex, Inc. | Interspinous spacer |
ES2488990T3 (es) | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2009123164A1 (ja) * | 2008-04-02 | 2009-10-08 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体 |
WO2011084477A2 (en) | 2009-12-15 | 2011-07-14 | Vertifex, Inc. | Spinal spacer for cervical and other vertebra, and associated systems and methods |
EP2531029B1 (en) | 2010-02-04 | 2016-10-19 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2011143469A1 (en) | 2010-05-12 | 2011-11-17 | Radius Health,Inc | Therapeutic regimens |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2013116823A1 (en) * | 2012-02-02 | 2013-08-08 | The Research Foundation Of State University Of New York | Benzimidazoles and uses thereof |
US9675303B2 (en) | 2013-03-15 | 2017-06-13 | Vertiflex, Inc. | Visualization systems, instruments and methods of using the same in spinal decompression procedures |
US10287617B2 (en) | 2014-03-11 | 2019-05-14 | Colorado State University Research Foundation | Methods for in vitro—in vivo efficacy determination |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
EP3834824A1 (en) | 2014-03-28 | 2021-06-16 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
EP3139848A4 (en) | 2014-05-07 | 2018-06-13 | Vertiflex, Inc. | Spinal nerve decompression systems, dilation systems, and methods of using the same |
EP3245204A4 (en) | 2015-01-17 | 2018-10-03 | Jiang, Jean, X. | Small molecules for the treatment of primary cancer and cancer metastasis |
WO2017223115A1 (en) | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ,インコーポレイテッド | Rad1901-2hclの多形性形態 |
US11400096B2 (en) | 2017-10-19 | 2022-08-02 | Board Of Regents, The University Of Texas System | Small molecules for the treatment of autoimmune disorders |
SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE947610C (de) * | 1955-04-30 | 1956-08-23 | Basf Ag | Verfahren zur Herstellung von Benzimidazoinen |
US3325271A (en) * | 1963-07-17 | 1967-06-13 | United States Borax Chem | Herbicidal composition and method employing substituted benzimidazoles |
US3897432A (en) * | 1971-04-21 | 1975-07-29 | Merck & Co Inc | Substituted benzimidazole derivatives |
SE357932B (es) * | 1972-01-27 | 1973-07-16 | Malaga Ab | |
US3987182A (en) * | 1974-06-17 | 1976-10-19 | Schering Corporation | Novel benzimidazoles useful as anti-androgens |
NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
JPH05163246A (ja) * | 1991-12-17 | 1993-06-29 | Nippon Oil & Fats Co Ltd | ペルフルオロ−オキサ−アルキル基含有ベンズイミダゾール誘導体及びその製造方法 |
GB9310069D0 (en) * | 1993-05-17 | 1993-06-30 | Zeneca Ltd | Heterocyclic compounds |
-
2005
- 2005-09-26 CA CA002582356A patent/CA2582356A1/en not_active Abandoned
- 2005-09-26 WO PCT/US2005/034462 patent/WO2006039243A1/en active Application Filing
- 2005-09-26 US US11/235,024 patent/US7566733B2/en active Active
- 2005-09-26 JP JP2007534694A patent/JP4953456B2/ja not_active Expired - Fee Related
- 2005-09-26 AU AU2005292345A patent/AU2005292345B9/en not_active Ceased
- 2005-09-26 CN CN2005800407430A patent/CN101065363B/zh not_active Expired - Fee Related
- 2005-09-26 EP EP05800116.5A patent/EP1805147B1/en not_active Not-in-force
- 2005-09-28 MY MYPI20054572A patent/MY147985A/en unknown
- 2005-09-29 AR ARP050104117A patent/AR050966A1/es active IP Right Grant
- 2005-09-29 TW TW094133855A patent/TW200621725A/zh unknown
-
2009
- 2009-06-22 US US12/488,752 patent/US7879895B2/en not_active Expired - Fee Related
-
2010
- 2010-12-16 US US12/970,554 patent/US8586616B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7879895B2 (en) | 2011-02-01 |
EP1805147B1 (en) | 2014-08-13 |
TW200621725A (en) | 2006-07-01 |
US7566733B2 (en) | 2009-07-28 |
EP1805147A1 (en) | 2007-07-11 |
AU2005292345B9 (en) | 2011-12-15 |
JP4953456B2 (ja) | 2012-06-13 |
CN101065363A (zh) | 2007-10-31 |
US20090258909A1 (en) | 2009-10-15 |
AU2005292345A1 (en) | 2006-04-13 |
WO2006039243A1 (en) | 2006-04-13 |
US20110086883A1 (en) | 2011-04-14 |
AU2005292345B2 (en) | 2011-12-01 |
CN101065363B (zh) | 2012-05-02 |
JP2008514707A (ja) | 2008-05-08 |
MY147985A (en) | 2013-02-28 |
CA2582356A1 (en) | 2006-04-13 |
US8586616B2 (en) | 2013-11-19 |
US20060116412A1 (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050966A1 (es) | Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) | |
AR050967A1 (es) | Derivados de bencimidazol utiles como moduladores de los receptores androgenicos (sarms) | |
AR048643A1 (es) | Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms) | |
ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
AR040030A1 (es) | Moduladores biciclicos de la funcion del receptor de androgeno | |
AR048644A1 (es) | Derivados del indol como moduladores selectivos de los receptores androgenicos (sarms) | |
AR048723A1 (es) | Derivados de indol como moduladores selectivos del receptor de androgenos (sarms) | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
AR055177A1 (es) | Compuestos heterociclicos fusionados utiles como moduladores de cinasa | |
DOP2007000018A (es) | Moduladores de indol sulfonamida de receptores de progesterona | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR055202A1 (es) | Derivados de imidazolcarboxamida como inhibidores de fructosa -1,6- biofosfatasa y composiciones farmaceuticas que los contienen | |
AR043436A1 (es) | Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6 | |
PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
AR064521A1 (es) | Activador de glucoquinasa | |
AR065795A1 (es) | Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros. | |
CU20090072A7 (es) | Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación | |
ECSP088648A (es) | Nuevos bencimidazoles 2-sustituidos como moduladores de receptor de androgeno selectivos (sarms) | |
ECSP088457A (es) | Compuestos de benzamida útiles como inhibidores de la histona deacetilasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |